The impact of dietary interventions on cardiometabolic health

Cardiovasc Diabetol. 2025 May 31;24(1):234. doi: 10.1186/s12933-025-02766-w.ABSTRACTObesity and cardiometabolic diseases are leading causes of morbidity and mortality among adults worldwide. These conditions significantly contribute to and exacerbate other major causes of illness and death, includin

E Erind Gjermeni

Additive impact of chronic obstructive pulmonary disease (COPD) and cardiovascular disease(CVD) on all-cause and disease-Specific mortality: a longitudinal nationwide population-based study

BMC Pulm Med. 2025 May 31;25(1):275. doi: 10.1186/s12890-025-03688-9.ABSTRACTBACKGROUND: Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are two age-related diseases commonly found in the elderly population, and they are associated with severe health consequences. Howev

Y Yanling Li

Long-term safety and efficacy of ivabradine after direct percutaneous coronary intervention in patients with acute myocardial infarction complicated by heart failure: a single-center retrospective study

BMC Cardiovasc Disord. 2025 May 31;25(1):422. doi: 10.1186/s12872-025-04854-x.ABSTRACTBACKGROUND: There are few studies on the long-term efficacy and safety of ivabradine in patients with acute myocardial infarction (AMI) complicated by heart failure. We aimed to assess the above questions and provi

X Xiaohua Guo

The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa

J Pediatr. 2025 May 29:114664. doi: 10.1016/j.jpeds.2025.114664. Online ahead of print.ABSTRACTOBJECTIVE: To evaluate long-term safety and efficacy of avalglucosidase alfa in children with infantile-onset Pompe disease (IOPD) experiencing clinical decline (cohorts 1 and 2) or suboptimal response (co

D David Kronn